A biotech worried older participants would struggle with eCOA, and Medable support delivered over 90% adherence in its vaccine trial.
The company feared trial participants aged 50+ would find eCOA technology hard to adopt, risking disengagement and unreliable data. Medable supported the vaccine trial with its eCOA technology and participant support. The page reports over 90% adherence to eCOA.
Medable is a digital clinical trial platform used by pharma sponsors for eCOA, eConsent and decentralized trial delivery
This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.
Published by Medable on its own site — read the original case study on bioprocessonline.com ↗
Note: Hosted on a trade-press site as a short vendor case study; no product names beyond eCOA.
Related use cases
- 01A top-10 pharma built three Phase III oncology studies in parallel across 30 countries on Medable's platform.
- 02A top-5 pharma scaled global vaccine mega-trials with Medable's eCOA and AI-assisted study build tools.
- 03A top pharma ran a long-term follow-up obesity trial on Medable without an EDC and kept 97% of patients.
- 04ICON and Medable reached 85% eConsent adoption across 1,200+ participants in a menopause study.
- 05Transforming Content Operations for 2x Faster Time to Market
- 06Astellas: Breaking Access Barriers with Veeva Compliant Chat